Seagen Inc. Share Price and Company Fundamentals
Last traded: Today at 8:00 PM
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
|Industry / Sector||Biotechnology / Healthcare|
|Full time employees||2092|
|Mailing address||21823 30th Drive SE Bothell WA 98021 United States|
|Phone / Fax||425 527 4000 /|
Seagen Inc. does not pay dividends.
As of Sep 2021, following are the company executives and directors listed on Seagen Inc..
|Dr. Clay B. Siegall||Co-Founder, Chairman, Pres & CEO||59||2.64M|
|Mr. Todd E. Simpson||Chief Financial Officer||59||620.67k|
|Ms. Jean I. Liu J.D., M.S.||Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec.||52||963.45k|
|Mr. Charles R. Romp||Exec. VP of Commercial U.S.||52||829.16k|
|Dr. Roger D. Dansey M.D.||Chief Medical Officer||63||1.65M|
|Dr. Vaughn B. Himes||Chief Technical Officer||59|
|Peggy Pinkston||VP of Investor Relations|
|Ms. Natasha A. Hernday||Exec. VP of Corp. Devel.||48|
|Mr. Matt Skelton||VP of Marketing|
|Mr. Christopher P. Pawlowicz||Exec. VP of HR|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Seagen Inc. is 29.35B and its enterprise value is 27.87B. The enterprise value to revenue ratio of SGEN is 11.69.
The SGEN's stocks Beta value is 0.82 making it 18% less volatile compared to NASDAQ market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Seagen Inc. (NASDAQ:SGEN) Frequently Asked Questions
1. What is Seagen Inc.'s Stock Symbol?
Seagen Inc. trades on NASDAQ under the ticker symbol "SGEN".
2. What is Seagen Inc.'s stock price today?
One share of SGEN stock can currently be purchased for approximately $161.34.
3. How can I contact Seagen Inc.?
Seagen Inc.'s mailing address is 21823 30th Drive SE Bothell WA 98021 United States. The company can be reached via phone at 425 527 4000.
4. What is Seagen Inc.'s official website?
The official website of Seagen Inc. is http://www.seagen.com.